

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): August 8, 2023

EHEALTH, INC.

(Exact Name of Registrant as Specified in its Charter)

001-33071

(Commission File Number)

56-2357876

(I.R.S. Employer Identification No.)

Delaware
(State or other jurisdiction of incorporation)

2625 AUGUSTINE DRIVE, SUITE 150
SANTA CLARA, CA 95054

(Address of principal executive offices) (Zip Code)

(650) 210-3150

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	EHTH	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2023, eHealth, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023 and its financial condition as of June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On August 8, 2023, the Company posted supplemental investor material on its investor relations webpage at <https://ir.ehealthinsurance.com>. The Company intends to use its investor relations webpage as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. A copy of the supplemental investor materials is also furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K and the exhibits attached hereto are intended to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Except as shall be expressly set forth by specific reference in such filing, the information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of eHealth, Inc. dated August 8, 2023 (eHealth, Inc. Announces Second Quarter 2023 Results)
99.2	Financial Results Conference Call Slides of eHealth, Inc. dated August 8, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 8, 2023

eHealth, Inc.

/s/ John Stelben

John Stelben
Chief Financial Officer
(Principal Financial Officer)



eHealth, Inc. Announces Second Quarter 2023 Results

Strong second quarter results; 2023 guidance increased

SANTA CLARA, California — August 8, 2023 — eHealth, Inc. (Nasdaq: EHTH), a leading private online health insurance marketplace, today announced its financial results for the second quarter ended June 30, 2023.

CEO Comments

"eHealth delivered strong second quarter results with revenue and profitability ahead of our expectations driven in part by positive tail revenue, which reflects favorable commissions and persistency trends in our book of business and further validates our commissions receivable asset. We are well on track in our preparations for the Annual Enrollment Period and I am confident in eHealth's ability to execute against our goal of returning to Medicare enrollment growth on a significantly improved operational and cost foundation in the fourth quarter. Further, the mid-point of our updated 2023 guidance now reflects adjusted EBITDA profitability, an important milestone for the organization." – Fran Soistman, Chief Executive Officer

Results Overview

- Q2 2023 revenue increased 32% year over year to \$66.8 million, including \$18.7 million in positive net adjustment revenue reflective of positive trends in persistency and commissions.
- Q2 2023 total operating costs and expenses decreased 3% to \$92.9 million compared to \$95.9 million in Q2 2022 due to continued emphasis on financial discipline, partially offset by investment in advisor headcount ahead of the annual enrollment period.
- Q2 2023 net loss of \$23.5 million improved \$14.0 million compared to Q2 2022 net loss of \$37.5 million.
- Q2 2023 adjusted EBITDA⁽¹⁾ of \$(14.8) million improved \$18.4 million compared to Q2 2022.
- Q2 2023 cash used in operations of \$9.4 million improved \$16.3 million compared to Q2 2022.
- \$189.8 million in cash, cash equivalents and marketable securities as of June 30, 2023.
- Commissions receivable balance of \$789.6 million as of June 30, 2023.
- Sales, marketing and digital organizations preparing successfully for the annual enrollment period, on track to return to Medicare enrollment growth on a substantially improved operational and cost foundation in the fourth quarter.

Note: See the tables at the end of this press release for a reconciliation of our GAAP financial measures to our non-GAAP financial measures for the relevant periods and footnote (1) on page 13 at the end of this press release for definitions of our non-GAAP financial measures.

2023 Guidance

Based on information available as of August 8, 2023, we are revising guidance for the full year ending December 31, 2023. These expectations are forward-looking statements and we assume no obligation to update these statements. Actual results may be materially different and are affected by the risk factors and uncertainties identified in this press release and in eHealth's annual and quarterly reports filed with the Securities and Exchange Commission.

The following guidance is for the full year ending December 31, 2023:

- Total revenue is expected to be in the range of \$439 million to \$459 million compared to our prior guidance of \$420 million to \$440 million.
- GAAP net loss is expected to be in the range of \$46 million to \$26 million compared to our prior guidance of \$55 million to \$35 million.
- Adjusted EBITDA⁽¹⁾ is expected to be in the range of \$(3) million to \$17 million compared to our prior guidance of \$(15) million to \$5 million.
- Operating cash flow is expected to be in the range of \$(30) million to \$(15) million, consistent with our previously issued guidance.

Webcast and Conference Call Information

A webcast and conference call will be held today, Tuesday, August 8, 2023 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Individuals interested in listening to the conference call may do so by dialing (888) 259-6580. The participant passcode is 88325951. The live and archived webcast of the call will also be available under "News and Events" on the Investor Relations page of our website at <https://ir.ehealthinsurance.com>.

About eHealth, Inc.

For over 25 years, eHealth, Inc. (Nasdaq: EHTH) has expertly guided American consumers with innovative technology and licensed advisor support to help them find health insurance and related options. Through its proprietary health insurance marketplace at eHealth.com, eHealth has connected more than eight million members with quality, affordable coverage. eHealth offers Medicare Advantage, Medicare Supplement, Medicare Part D, individual, family, small business, and ancillary plans from approximately 200 health insurance companies nationwide. For more information about eHealth, please visit us at eHealth.com, or follow us on [LinkedIn](#), [Facebook](#), [Instagram](#), and [Twitter](#).

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding our expectations for enrollment growth and quality, our expectations regarding our financial performance, our preparation for the annual enrollment period, our expectations regarding our operations and costs, our estimates regarding total membership, Medicare, individual and family plan, ancillary products and small business memberships, our estimates regarding constrained lifetime values of commissions per approved member by product category, our estimates regarding cash collections from members approved in prior periods, our estimates regarding costs per approved member, and our 2023 annual guidance for total revenue, GAAP net loss, adjusted EBITDA and operating cash flow.

These forward-looking statements are inherently subject to various risks and uncertainties that could cause actual results to differ materially from the statements made. In particular, we are required by Accounting Standards Codification 606 — *Revenue from Contracts with Customers* to make numerous assumptions that are based on historical trends and our management's judgment. These assumptions may change over time and have a material impact on our revenue recognition, guidance, and results of operations. Please review the assumptions stated in this press release carefully.

The risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to retain existing members and enroll new members during the annual healthcare open enrollment period, the Medicare annual enrollment period, the Medicare Advantage open enrollment

period and other special enrollment periods; changes in laws, regulations and guidelines, including in connection with healthcare reform or with respect to the marketing and sale of Medicare plans; competition, including competition from government-run health insurance exchanges and other sources; the seasonality of our business and the fluctuation of our operating results; our ability to accurately estimate membership, lifetime value of commissions and commissions receivable; changes in product offerings among carriers on our ecommerce platform and changes in our estimated conversion rate of an approved member to a paying member and the resulting impact of each on our commission revenue; the concentration of our revenue with a small number of health insurance carriers; our ability to execute on our growth strategy and other business initiatives; changes in our management and key employees; our ability to hire, train, retain and ensure the productivity of licensed health insurance agents and other employees; exposure to security risks and our ability to safeguard the security and privacy of confidential data; our relationships with health insurance carriers; the success of our carrier advertising and sponsorship program; our success in marketing and selling health insurance plans and our unit cost of acquisition; our ability to effectively manage our operations as our business evolves and execute on our transformation plan and other strategic initiatives; the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products; changes in the market for private health insurance; consumer satisfaction of our service and actions we take to improve the quality of enrollments; changes in member conversion rates; changes in commission rates; our ability to sell qualified health insurance plans to subsidy-eligible individuals and to enroll subsidy-eligible individuals through government-run health insurance exchanges; our ability to maintain and enhance our brand identity; our ability to derive desired benefits from investments in our business, including membership growth and retention initiatives; reliance on marketing partners; the impact of our direct-to-consumer mail, email, social media, telephone and television marketing efforts; timing of receipt and accuracy of commission reports; payment practices of health insurance carriers; dependence on our operations in China; the restrictions in our debt obligations; the restrictions in our investment agreement with convertible preferred stock investors; our ability to raise additional capital; compliance with insurance, privacy and other laws and regulations; the outcome of litigation in which we may from time to time be involved; the performance, reliability and availability of our information technology systems, ecommerce platform and underlying network infrastructure, including any new systems we may implement; public health crises, pandemics, natural disasters, changing climate conditions and other extreme events; general economic conditions, including inflation, recession, financial, banking and credit market disruptions; and our ability to affectively administer our self-insurance program. Other factors that could cause operating, financial and other results to differ are described in our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on the Investor Relations page of our website at <http://www.ehealthinsurance.com> and on the Securities and Exchange Commission's website at www.sec.gov.

All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Relations Contact

Kate Sidorovich, CFA
Senior Vice President, Investor Relations & Strategy
2625 Augustine Drive, Suite 150
Santa Clara, CA, 95054
kate.sidorovich@ehealth.com
<http://ir.ehealthinsurance.com>

EHEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, unaudited)

	June 30, 2023	December 31, 2022
Assets		
Current assets:		
Cash and cash equivalents	\$ 153,185	\$ 144,401
Short-term marketable securities	36,619	—
Accounts receivable	643	2,633
Contract assets – commissions receivable – current	188,697	242,749
Prepaid expenses and other current assets	11,083	11,301
Total current assets	390,227	401,084
Contract assets – commissions receivable – non-current	600,892	641,555
Property and equipment, net	5,034	5,501
Operating lease right-of-use assets	23,938	26,516
Restricted cash	3,239	3,239
Other assets	30,105	34,716
Total assets	\$ 1,053,435	\$ 1,112,611
Liabilities, convertible preferred stock and stockholders' equity		
Current liabilities:		
Accounts payable	\$ 6,391	\$ 6,732
Accrued compensation and benefits	20,969	20,690
Accrued marketing expenses	6,435	23,770
Lease liabilities – current	6,498	6,486
Other current liabilities	4,452	2,887
Total current liabilities	44,745	60,565
Long-term debt	66,905	66,129
Deferred income taxes – non-current	25,659	32,359
Lease liabilities – non-current	30,907	34,187
Other non-current liabilities	4,315	5,132
Total liabilities	172,531	198,372
Convertible preferred stock	279,995	263,284
Stockholders' equity:		
Common stock	40	40
Additional paid-in capital	788,222	777,187
Treasury stock, at cost	(199,998)	(199,998)
Retained earnings	12,836	73,799
Accumulated other comprehensive loss	(191)	(73)
Total stockholders' equity	600,909	650,955
Total liabilities, convertible preferred stock and stockholders' equity	\$ 1,053,435	\$ 1,112,611

EHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)

	Three Months Ended June 30,		% Change	Six Months Ended June 30,		% Change
	2023	2022		2023	2022	
Revenue:						
Commission	\$ 60,186	\$ 47,835	26 %	\$ 128,189	\$ 141,685	(10)%
Other	6,582	2,574	156 %	12,302	13,974	(12)%
Total revenue	66,768	50,409	32 %	140,491	155,659	(10)%
Operating costs and expenses^(a):						
Cost of revenue	253	423	(40)%	468	296	58 %
Marketing and advertising	23,284	29,963	(22)%	56,183	88,417	(36)%
Customer care and enrollment	32,862	29,149	13 %	59,819	71,313	(16)%
Technology and content	14,500	17,780	(18)%	30,044	37,443	(20)%
General and administrative	22,021	17,198	28 %	43,023	37,185	16 %
Impairment, restructuring and other charges	—	1,369	(100)%	—	6,192	(100)%
Total operating costs and expenses	92,920	95,882	(3)%	189,537	240,846	(21)%
Loss from operations	(26,152)	(45,473)	42 %	(49,046)	(85,187)	42 %
Other income (expense), net	108	(1,167)	109 %	(484)	(2,188)	78 %
Loss before income taxes	(26,044)	(46,640)	44 %	(49,530)	(87,375)	43 %
Benefit from income taxes	(2,543)	(9,138)		(6,151)	(17,131)	
Net loss	(23,501)	(37,502)	37 %	(43,379)	(70,244)	38 %
Preferred stock dividends	(5,223)	(4,771)		(10,324)	(9,488)	
Change in preferred stock redemption value	(4,191)	(2,756)		(7,260)	(5,257)	
Net loss attributable to common stockholders	\$ (32,915)	\$ (45,029)	27 %	\$ (60,963)	\$ (84,989)	28 %
Net loss per share attributable to common stockholders:						
Basic and diluted	\$ (1.18)	\$ (1.65)	28 %	\$ (2.20)	\$ (3.12)	29 %
Weighted-average number of shares used in per share:						
Basic and diluted	27,822	27,276	2 %	27,735	27,283	2 %
^(a) Includes stock-based compensation expense as follows:						
Marketing and advertising	\$ 538	\$ 428		\$ 993	\$ 741	
Customer care and enrollment	788	512		1,393	966	
Technology and content	1,173	1,821		2,078	3,671	
General and administrative	3,694	2,744		6,723	5,412	
Total stock-based compensation expense	\$ 6,193	\$ 5,505	12 %	\$ 11,187	\$ 10,790	4 %
Non-GAAP Results⁽¹⁾:						
Adjusted EBITDA	\$ (14,808)	\$ (33,250)	55 %	\$ (27,463)	\$ (58,078)	53 %
Adjusted EBITDA margin	(22)%	(66)%	66 %	(20)%	(37)%	48 %

Note: See accompanying footnotes on page 13.

EHEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Operating activities:				
Net loss	\$ (23,501)	\$ (37,502)	\$ (43,379)	\$ (70,244)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:				
Depreciation and amortization	638	1,091	1,294	2,037
Amortization of internally developed software	4,513	4,258	9,102	8,090
Stock-based compensation expense	6,193	5,505	11,187	10,790
Deferred income taxes	(3,089)	(9,284)	(6,700)	(17,316)
Other non-cash items	(162)	914	(101)	1,129
Changes in operating assets and liabilities:				
Accounts receivable	384	1,536	1,989	5,309
Contract assets – commissions receivable	12,505	29,474	95,012	106,616
Prepaid expenses and other assets	1	2,238	(124)	14,656
Accounts payable	872	(2,386)	(621)	(7,911)
Accrued compensation and benefits	(6,914)	(6,656)	279	(4,614)
Accrued marketing expenses	(2,317)	(9,867)	(17,336)	(26,715)
Deferred revenue	655	1,003	283	780
Accrued expenses and other liabilities	794	(6,090)	490	(1,261)
Net cash provided by (used in) operating activities	(9,428)	(25,766)	51,375	21,346
Investing activities:				
Capitalized internal-use software and website development costs	(2,038)	(4,171)	(4,202)	(8,376)
Purchases of property and equipment and other assets	(306)	(172)	(373)	(227)
Purchases of marketable securities	(26,593)	(4,464)	(48,602)	(8,402)
Proceeds from redemption and maturities of marketable securities	12,400	10,950	12,400	45,269
Net cash provided by (used in) investing activities	(16,537)	2,143	(40,777)	28,264
Financing activities:				
Net proceeds from debt financing	—	—	—	64,862
Net proceeds from exercise of common stock options and employee stock purchases	262	—	262	1,054
Repurchase of shares to satisfy employee tax withholding obligations	(623)	(1,926)	(1,051)	(2,434)
Principal payments in connection with leases	(14)	(29)	(25)	(64)
Payments of preferred stock dividends	(873)	—	(873)	—
Net cash provided by (used in) financing activities	(1,248)	(1,955)	(1,687)	63,418
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(235)	(244)	(127)	(213)
Net increase (decrease) in cash, cash equivalents and restricted cash	(27,448)	(25,822)	8,784	112,815
Cash, cash equivalents and restricted cash at beginning of period	183,872	223,802	147,640	85,165
Cash, cash equivalents and restricted cash at end of period	\$ 156,424	\$ 197,980	\$ 156,424	\$ 197,980

EHEALTH, INC.
SEGMENT INFORMATION
(in thousands, unaudited)

We evaluate our business performance and manage our operations as two distinct reporting segments: Medicare and Individual, Family and Small Business. This identification of reportable segments is consistent with how the segments report to and are managed by our chief executive officer, who is our chief operating decision maker. The Medicare segment consists primarily of amounts earned from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans (collectively, the "Medicare Plans"), fees for the performance of administrative services and to a lesser extent, amounts from our sale of ancillary products sold to our Medicare-eligible customers, including but not limited to, dental and vision plans, as well as amounts we are paid in connection with our advertising program for marketing and other services. The Individual, Family and Small Business segment consists primarily of amounts earned from our sale of individual, family and small business health insurance plans, including both qualified and non-qualified plans, and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, dental, vision, and short-term insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties for the use of our health insurance ecommerce technology, and our delivery and sale to third parties of individual and family health insurance plan leads generated by our ecommerce platforms and our marketing activities.

Marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect marketing and advertising, customer care and enrollment and technology and content operating expenses are allocated to each segment based on usage. Corporate consists of other indirect general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, which are managed in a corporate shared services environment and, since they are not the responsibility of segment operating management, are not allocated to the reportable segments and are instead reported within Corporate.

The performance of each reportable segment is evaluated based on several factors, including revenue and segment profit (loss), which is calculated as total revenue for the applicable segment less direct and indirect allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization and impairment, restructuring and other charges. Senior management uses segment profit (loss) to evaluate segment performance because they believe this measure is indicative of performance trends and the overall earnings potential of each segment.

	Three Months Ended June 30,			Six Months Ended June 30,		
	2023	2022	% Change	2023	2022	% Change
Revenue:						
Medicare	\$ 55,430	\$ 41,062	35 %	\$ 117,264	\$ 136,129	(14)%
Individual, Family and Small Business	11,338	9,347	21 %	23,227	19,530	19 %
Total revenue	\$ 66,768	\$ 50,409	32 %	\$ 140,491	\$ 155,659	(10)%
Segment profit (loss):						
Medicare	\$ (4,695)	\$ (25,271)	81 %	\$ (8,068)	\$ (40,088)	80 %
Individual, Family and Small Business	6,693	4,343	54 %	14,106	9,597	47 %
Segment profit (loss)	1,998	(20,928)	110 %	6,038	(30,491)	120 %
Corporate	(16,806)	(12,322)		(33,501)	(27,587)	
Stock-based compensation expense	(6,193)	(5,505)		(11,187)	(10,790)	
Depreciation and amortization	(5,151)	(5,349)		(10,396)	(10,127)	
Impairment, restructuring and other charges	—	(1,369)		—	(6,192)	
Other income (expense), net	108	(1,167)		(484)	(2,188)	
Loss before income taxes	\$ (26,044)	\$ (46,640)	44 %	\$ (49,530)	\$ (87,375)	43 %

EHEALTH, INC.
COMMISSION REVENUE
(in thousands, unaudited)

Our commission revenue results from approval of an application from health insurance carriers, which we define as our customers under Accounting Standards Codification 606 — *Revenue from Contracts with Customers* ("ASC 606"). Our commission revenue is primarily comprised of commissions from health insurance carriers which is computed using the estimated constrained lifetime values as the "constrained LTVs" of commission payments that we expect to receive. Our commissions include regular payments with respect to administrative services we perform. Our Medicare Supplement plan commissions include certain bonus payments, which are generally based on our attaining predetermined target sales levels or other objectives, as determined by the health insurance carriers.

The following table presents commission revenue by product for the periods indicated:

	Three Months Ended June 30,			Six Months Ended June 30,		
	2023	2022	% Change	2023	2022	% Change
Medicare						
Medicare Advantage	\$ 45,389	\$ 36,477	24 %	\$ 99,510	\$ 114,607	(13)%
Medicare Supplement	1,091	2,637	(59)%	5,156	8,757	(41)%
Medicare Part D	1,863	(462)	503 %	2,640	998	165 %
Total Medicare	48,343	38,652	25 %	107,306	124,362	(14)%
Individual and Family	4,741	3,114	52 %	8,747	6,240	40 %
Ancillary	2,521	2,648	(5)%	4,943	5,479	(10)%
Small Business	3,800	2,423	57 %	8,673	5,906	47 %
Commission Bonus and Other	781	998	(22)%	(1,480)	(302)	(390)%
Total Commission Revenue	\$ 60,186	\$ 47,835	26 %	\$ 128,189	\$ 141,685	(10)%

The following table presents a summary of commission revenue by segment for the periods indicated:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Medicare				
Commission Revenue from Members Approved During the Period	\$ 36,006	\$ 49,855	\$ 92,623	\$ 134,138
Net Commission Revenue from Members Approved in Prior Periods ^(a)	13,403	(10,788)	13,455	(10,737)
Total Medicare Segment Commission Revenue	49,409	39,067	106,078	123,401
Individual, Family and Small Business				
Commission Revenue from Members Approved During the Period	3,298	4,612	10,006	10,654
Commission Revenue from Renewals of Small Business Members During the Period	2,158	2,044	5,271	5,081
Net Commission Revenue from Members Approved in Prior Periods ^(a)	5,321	2,112	6,834	2,549
Total Individual, Family and Small Business Segment Commission Revenue	10,777	8,768	22,111	18,284
Total Commission Revenue	\$ 60,186	\$ 47,835	\$ 128,189	\$ 141,685

^(a) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. The total reductions to revenue from members approved in prior periods were \$2.9 million for the three and six months ended June 30, 2023 and \$13.7 million for the three and six months ended June 30, 2022. These reductions to revenue primarily relate to the Medicare segment.

EHEALTH, INC.
SUMMARY OF SELECTED METRICS
(in thousands, except member and per member data, unaudited)

Selected Metrics — Second Quarter of 2023

	Three Months Ended June 30,		% Change
	2023	2022	
Approved Members⁽²⁾			
Medicare			
Medicare Advantage	35,597	51,506	(31)%
Medicare Supplement	2,923	3,092	(5)%
Medicare Part D	2,948	4,845	(39)%
Total Medicare	41,468	59,443	(30)%
Individual and Family	4,285	4,601	(7)%
Ancillary	13,051	18,266	(29)%
Small Business	1,964	1,825	8 %
Total Approved Members	60,768	84,135	(28)%
Constrained Lifetime Value of Commissions per Approved Member⁽³⁾			
Medicare^(a)			
Medicare Advantage	\$ 891	\$ 886	1 %
Medicare Supplement	875	913	(4)%
Medicare Part D	231	207	12 %
Individual and Family			
Non-Qualified Health Plans	329	327	1 %
Qualified Health Plans	357	340	5 %
Ancillary			
Short-term	161	167	(4)%
Dental	98	99	(1)%
Vision	66	60	10 %
Small Business	229	201	14 %
^(a) Constraints for all Medicare products remained the same for the periods presented.			
Expense Metrics per Approved Member⁽⁴⁾			
Medicare			
Customer care and enrollment cost per Medicare Advantage ("MA")-equivalent approved member	\$ 774	\$ 486	59 %
Variable marketing cost per MA-equivalent approved member	396	410	(3)%
Total acquisition cost per MA-equivalent approved member	\$ 1,170	\$ 896	31 %
Individual and Family Plan ("IFP")			
Customer care and enrollment cost per IFP-equivalent approved member	\$ 252	\$ 149	69 %
Variable marketing cost per IFP-equivalent approved member	56	102	(45)%
Total acquisition cost per IFP-equivalent approved member	\$ 308	\$ 251	23 %

Note: See accompanying footnotes on page 13.

EHEALTH, INC.
SUMMARY OF SELECTED METRICS
(in thousands, except member and per member data, unaudited)

Selected Metrics — Six Months Ended June 30, 2023

	Six Months Ended June 30,		% Change
	2023	2022	
Approved Members⁽²⁾			
Medicare			
Medicare Advantage	96,048	133,937	(28)%
Medicare Supplement	7,508	9,648	(22)%
Medicare Part D	6,794	11,668	(42)%
Total Medicare	110,350	155,253	(29)%
Individual and Family	14,384	14,402	— %
Ancillary	29,707	37,236	(20)%
Small Business	3,903	4,339	(10)%
Total Approved Members	158,344	211,230	(25)%
	As of June 30,		% Change
	2023	2022	
Estimated Membership⁽⁵⁾			
Medicare⁽⁶⁾			
Medicare Advantage	572,799	589,553	(3)%
Medicare Supplement	94,372	104,414	(10)%
Medicare Part D	211,144	223,474	(6)%
Total Medicare	878,315	917,441	(4)%
Individual and Family⁽⁶⁾	90,082	101,802	(12)%
Ancillary⁽⁶⁾	196,141	224,649	(13)%
Small Business⁽⁷⁾	46,560	49,172	(5)%
Total Estimated Membership	1,211,098	1,293,064	(6)%

Note: See accompanying footnotes on page 13.

EHEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(unaudited)

Reconciliation of GAAP Operating Costs and Expenses to Non-GAAP Operating Costs and Expenses (in thousands)⁽¹⁾:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
GAAP marketing and advertising expense	\$ 23,284	\$ 29,963	\$ 56,183	\$ 88,417
Stock-based compensation expense	(538)	(428)	(993)	(741)
Non-GAAP marketing and advertising expense ⁽¹⁾	<u>\$ 22,746</u>	<u>\$ 29,535</u>	<u>\$ 55,190</u>	<u>\$ 87,676</u>
GAAP customer care and enrollment expense	\$ 32,862	\$ 29,149	\$ 59,819	\$ 71,313
Stock-based compensation expense	(788)	(512)	(1,393)	(966)
Non-GAAP customer care and enrollment expense ⁽¹⁾	<u>\$ 32,074</u>	<u>\$ 28,637</u>	<u>\$ 58,426</u>	<u>\$ 70,347</u>
GAAP technology and content expense	\$ 14,500	\$ 17,780	\$ 30,044	\$ 37,443
Stock-based compensation expense	(1,173)	(1,821)	(2,078)	(3,671)
Non-GAAP technology and content expense ⁽¹⁾	<u>\$ 13,327</u>	<u>\$ 15,959</u>	<u>\$ 27,966</u>	<u>\$ 33,772</u>
GAAP general and administrative expense	\$ 22,021	\$ 17,198	\$ 43,023	\$ 37,185
Stock-based compensation expense	(3,694)	(2,744)	(6,723)	(5,412)
Non-GAAP general and administrative expense ⁽¹⁾	<u>\$ 18,327</u>	<u>\$ 14,454</u>	<u>\$ 36,300</u>	<u>\$ 31,773</u>
GAAP operating costs and expenses	\$ 92,920	\$ 95,882	\$ 189,537	\$ 240,846
Stock-based compensation expense	(6,193)	(5,505)	(11,187)	(10,790)
Impairment, restructuring and other charges	—	(1,369)	—	(6,192)
Non-GAAP operating costs and expenses ⁽¹⁾	<u>\$ 86,727</u>	<u>\$ 89,008</u>	<u>\$ 178,350</u>	<u>\$ 223,864</u>

Reconciliation of GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA and Adjusted EBITDA Margin (in thousands)⁽¹⁾:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
GAAP net loss attributable to common stockholders	\$ (32,915)	\$ (45,029)	\$ (60,963)	\$ (84,989)
Preferred stock dividends	5,223	4,771	10,324	9,488
Change in preferred stock redemption value	4,191	2,756	7,260	5,257
GAAP net loss	(23,501)	(37,502)	(43,379)	(70,244)
Stock-based compensation expense	6,193	5,505	11,187	10,790
Depreciation and amortization	5,151	5,349	10,396	10,127
Impairment, restructuring and other charges	—	1,369	—	6,192
Other income (expense), net	(108)	1,167	484	2,188
Benefit from income taxes	(2,543)	(9,138)	(6,151)	(17,131)
Adjusted EBITDA	<u>\$ (14,808)</u>	<u>\$ (33,250)</u>	<u>\$ (27,463)</u>	<u>\$ (58,078)</u>
Net income margin	(35)%	(74)%	(31)%	(45)%
Adjusted EBITDA margin	(22)%	(66)%	(20)%	(37)%

Note: See accompanying footnotes on page 13.

EHEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(unaudited)

Reconciliation of Guidance GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA (in millions)⁽¹⁾:

	Full Year 2023 Guidance			
	Low		High	
GAAP net loss attributable to common stockholders	\$	(84.0)	\$	(64.0)
Impact from preferred stock		38.0		38.0
GAAP net loss		(46.0)		(26.0)
Stock-based compensation expense		22.0		20.0
Depreciation and amortization		22.0		21.0
Impairment, restructuring and other charges		5.0		3.0
Other expense, net		7.0		6.0
Benefit from income taxes		(13.0)		(7.0)
Adjusted EBITDA	\$	(3.0)	\$	17.0

Note: See accompanying footnotes on page 13.

(1) **Non-GAAP Financial Information**

This press release includes financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). To supplement eHealth's condensed consolidated financial statements presented in accordance with GAAP, eHealth presents investors with non-GAAP financial measures, including non-GAAP operating costs and expenses, adjusted EBITDA and adjusted EBITDA margin.

- Non-GAAP operating costs and expenses are calculated by excluding the effect of expensing stock-based compensation related to stock options, restricted stock awards, performance-based and market-based awards and employee stock purchase plan. Total non-GAAP operating costs and expenses is calculated by excluding the effect of expensing stock-based compensation related to stock options, restricted stock awards, performance-based and market-based awards and employee stock purchase plan and impairment, restructuring and other charges.
- Adjusted EBITDA is calculated by excluding dividends for preferred stock and change in preferred stock redemption value (together "the impact from preferred stock"), income tax expense (benefit), depreciation and amortization, stock-based compensation expense, impairment, restructuring and other charges, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.
- Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.

eHealth believes that the presentation of these non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to eHealth's financial condition and results of operations. Management believes that the use of these non-GAAP financial measures provides consistency and comparability with eHealth's past financial reports. Management also believes that the items described above provide an additional measure of eHealth's operating results and facilitates comparisons of eHealth's core operating performance against prior periods and business model objectives. This information is provided to investors in order to facilitate additional analyses of past, present and future operating performance and as a supplemental means to evaluate eHealth's ongoing operations. eHealth believes that these non-GAAP financial measures are useful to investors in their assessment of eHealth's operating performance.

Non-GAAP operating costs and expenses, adjusted EBITDA and adjusted EBITDA margin are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures used in this press release have limitations in that they do not reflect all of the revenue and costs associated with the operations of eHealth's business and do not reflect income tax as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of eHealth's results as reported under GAAP. eHealth expects to continue to incur the stock-based compensation costs and depreciation and amortization described above, and exclusion of these costs, and their related income tax benefits, from non-GAAP financial measures should not be construed as an inference that these costs are unusual or infrequent. eHealth compensates for these limitations by prominently disclosing GAAP net income (loss), GAAP net income (loss) attributable to common stockholders and GAAP net income (loss) margin and providing investors with reconciliations from eHealth's GAAP operating results to the non-GAAP financial measures for the relevant periods.

The tables above provide more details on the GAAP financial measures that are most directly comparable to the non-GAAP financial measures described above and the related reconciliations between these financial measures.

- (2) Approved members represent the number of individuals on submitted applications that were approved by the relevant insurance carrier for the identified product during the current period. The applications may be submitted in either the current period or prior periods. Not all approved members ultimately become paying members.
- (3) Constrained lifetime value ("LTV") of commissions per approved member for Medicare, individual and family and ancillary plans represents commissions estimated to be collected over the estimated life of an approved member's plan after applying constraints in accordance with our revenue recognition policy. Constrained LTV of commissions per approved member for small business represents the estimated commissions we expect to collect from the plan over the following twelve months. The estimate is driven by multiple factors, including but not limited to, contracted commission rates, carrier mix, estimated average plan duration, the regulatory environment, and cancellations of insurance plans offered by health insurance carriers with which we have a relationship and applied constraints. The constraints are applied to help ensure that commissions estimated to be collected over the estimated life of an approved member's plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. These factors may result in varying values from period to period.
- (4) Expense Metrics per Approved Member: Marketing initiatives are an important component of our strategy to increase revenue and are primarily designed to encourage consumers to complete an application for health insurance. Variable marketing costs represents direct costs incurred in member acquisition from our direct, marketing partners and online advertising channels. Variable marketing costs exclude fixed overhead costs, such as personnel related costs, consulting expenses, facilities and other

operating costs allocated to the marketing and advertising department. In addition, we incur customer care and enrollment expenses in assisting applicants during the enrollment process.

The numerator used to calculate each metric is the portion of the respective operating expenses for marketing and advertising and customer care and enrollment that is directly related to member acquisition for our sale of Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans (collectively, the "Medicare Plans") and for all individual and family plans and short-term health insurance plans (collectively, the "IFP Plans"), respectively. The denominator used to calculate each metric is based on a derived metric that represents the relative value of the new members acquired. For Medicare Plans, we call this derived metric Medicare Advantage ("MA")-equivalent approved members, and for IFP Plans, we call this derived metric IFP-equivalent approved members. MA-equivalent approved members is a derived metric with a Medicare Part D approved member being weighted at 25% of a Medicare Advantage member and a Medicare Supplement member based on their relative LTVs at the time of our adoption of ASC 606. We calculate the number of MA-equivalent approved members by adding the total number of approved Medicare Advantage and Medicare Supplement members and 25% of the total number of approved Medicare Part D members during the periods presented. IFP-equivalent approved members is a derived metric with a short-term approved member being weighted at 33% of a major medical individual and family health insurance plan member based on their relative LTVs at the time of our adoption of ASC 606. We calculate the number of IFP-equivalent approved members by adding the total number of approved qualified and non-qualified health plan members and 33% of the total number of short-term approved members during the period presented.

- (5) Estimated membership represents the estimated number of members active as of the date indicated based on the number of members for whom we have received or applied a commission payment during the period of estimation.

Health insurance carriers bill and collect insurance premiums paid by our members. The carriers do not report to us the number of members that we have as of a given date. The majority of our members who terminate their policies do so by discontinuing their premium payments to the carrier or notifying the carrier directly and do not inform us of the cancellation. Also, some of our members pay their premiums less frequently than monthly. Given the number of months required to observe non-payment of commissions in order to confirm cancellations, we estimate the number of members who are active on insurance policies as of a specified date.

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was included in our estimates was in fact not an active member of ours. For instance, we reconcile information carriers provide to us and may determine that we were not historically paid commissions owed to us, which would cause us to have underestimated membership. Conversely, carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. We do not update our estimated membership numbers reported in previous periods. Instead, we reflect updated information regarding our historical membership in the membership estimate for the current period. If we experience a significant variance in historical membership as compared to our initial estimates, while we keep the prior period data consistent with previously reported amounts, we may provide the updated information in other communications or disclosures. As a result of the delay in our receipt of information from insurance carriers, actual trends in our membership are most discernible over periods longer than from one quarter to the next. As a result of the delay we experience in receiving information about our membership, it is difficult for us to determine with any certainty the impact of current conditions on our membership retention. Various circumstances could cause the assumptions and estimates that we make in connection with estimating our membership to be inaccurate, which would cause our membership estimates to be inaccurate.

- (6) To estimate the number of members on Medicare-related, individual and family, and ancillary health insurance plans, we take the respective sum of (i) the number of members for whom we have received or applied a commission payment for a month that may be up to three months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the period being estimated); and (ii) the number of approved members over that period (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations through the date of the estimate). To the extent we determine through confirmations from a health insurance carrier that a commission payment is delayed or is inaccurate as of the date of estimation, we adjust the estimated membership to also reflect the number of members for whom we expect to receive or to refund a commission payment. Further, to the extent we have received substantially all of the commission payments related to a given month during the period being estimated, we will take the number of members for whom we have received or applied a commission payment during the month of estimation. For ancillary health insurance plans, the one to three-month period varies by insurance product and is largely dependent upon the timeliness of commission payment and related reporting from the related carriers.
- (7) To estimate the number of members on small business health insurance plans, we use the number of initial members at the time the group was approved, and we update this number for changes in membership if such changes are reported to us by the group or carrier. However, groups generally notify the carrier directly of policy cancellations and increases or decreases in group size without informing us. Health insurance carriers often do not communicate policy cancellation information or group size changes to us. We often are made aware of policy cancellations and group size changes at the time of annual renewal and update our membership statistics accordingly in the period they are reported.



Q2 2023 Financial Results

Conference Call Slides

Safe Harbor Statement

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements in this presentation include, but are not limited to, the following: our estimates regarding Medicare enrollment growth; our estimates regarding commissions receivable collection and our retention rates; our estimates regarding operating cash flow for the twelve months ended March 31, 2024; our 2023 operational priorities; and our 2023 annual guidance for total revenue, GAAP net loss, adjusted EBITDA and operating cash flow. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in our filings with the Securities and Exchange Commission, including our latest Form 10-Q and 10-K. The forward-looking statements in this presentation are based on information available to us as of today, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Non-GAAP Information

This presentation includes both GAAP and non-GAAP financial measures. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for results prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures included in this presentation to the most directly comparable GAAP financial measures is available in the Appendix to this presentation. Management uses both GAAP and non-GAAP information in evaluating and operating its business internally and as such has determined that it is important to provide this information to investors.

Q2 2023 Highlights


- ✓ **Second quarter revenue growth and strong earnings performance** driven primarily by positive tail revenue of \$18.7 million.
- ✓ **Improved earnings** compared to prior year:
 - Q2 2023 GAAP net loss of \$23.5 million improved from Q2 2022 GAAP net loss of \$37.5 million.
 - Q2 2023 adjusted EBITDA⁽¹⁾ of \$(14.8) million improved from Q2 2022 adjusted EBITDA⁽¹⁾ of \$(33.3) million.
- ✓ **Q2 2023 total operating costs and expenses decreased 3%** to \$92.9 million compared to \$95.9 million in Q2 2022 due to continued emphasis on financial discipline, partially offset by investment in advisor headcount ramp ahead of the AEP.
- ✓ **Sales, marketing, and digital organizations ramping successfully for the AEP;** on track to meet our goal of returning to Medicare enrollment growth in the fourth quarter of 2023.
- ✓ **Q2 2023 operating cash flow** of \$(9.4) million improved from \$(25.8) million in Q2 2022.
- ✓ **Improving our FY 2023 guidance ranges** for total revenue, GAAP net loss, and adjusted EBITDA.
- ✓ **Made encouraging progress in improving retention rates,** most recent AEP cohort continues to retain better than prior two AEP cohorts.

(1) Adjusted EBITDA is calculated by excluding dividends for preferred stock and change in preferred stock redemption value (together "the impact from preferred stock"), income tax expense (benefit), depreciation and amortization, stock-based compensation expense, impairment, restructuring and other charges, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

Year-over-Year Improvements in Q2 Revenue & Profitability

Q2 '23 revenue increased by 32% year-over-year, driven primarily by positive net adjustment or tail revenue. Positive tail revenue also drove large year-over-year improvements in GAAP net loss and adjusted EBITDA⁽¹⁾.

Profitability improvement was also driven by a 3% year-over-year decline in GAAP operating expense.



(1) Adjusted EBITDA is calculated by excluding the impact from preferred stock, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, impairment, restructuring and other charges, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

Tail Revenue & Commissions Receivable Asset Strength

After recognizing an additional \$18.7 million in positive tail revenue this quarter, eHealth's cumulative tail revenue since transitioning to ASC 606 in 2018 now amounts to more than \$170 million.

Cumulative tail revenue recognized (\$, MM)



Significant cumulative tail revenue combined with stable LTVs underscore the reliability of eHealth's Commissions Receivable balance. We finished Q2 '23 with \$790 million in Commissions Receivable and expect to increase this asset further in connection with our expected return to enrollment growth in the fourth quarter.


Current & Non-Current Commissions Receivable as of June 30th (\$, MM)



Q2 Medicare Segment Performance

Q2 '23 Medicare approved members declined 30% driven by a 33% decline in variable advertising spend year-over-year.

Segment revenue and segment loss⁽¹⁾ both improved year-over-year, driven by positive tail revenue.






⁽¹⁾ Segment loss is calculated as total revenue for the applicable segment less direct and indirect allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, and impairment, restructuring and other charges.

Q2 Individual, Family and Small Business Segment Performance

Q2 '23 Individual, Family and Small Business segment revenue and segment profit⁽¹⁾ increased year-over-year, driven by higher LTVs for our IFP products and \$5.3 million in positive tail revenue for the segment.

Approved applications declined as a result of lower variable advertising spend year-over-year.



(1) Segment profit is calculated as total revenue for the applicable segment less direct and indirect allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, and impairment, restructuring and other charges.


Cash Flow & Liquidity Metrics

For the twelve-month period ended June 30th, 2023, operating cash flow was positive \$3.2 million. We reached this important milestone ahead of schedule and continue to expect to be at or above breakeven on operating cash flow for the twelve months ending March 31, 2024.



Total Cash Collected by Revenue Type

Total Q2 2023 cash collections of \$81.1M declined 1% year-over-year driven by our decision to slow down our enrollment growth over the past 12 months and partially offset by strong commissions collections on our existing book of business.



(1) We distinguish between commission and non-commission based cash collections using the same methodology we use to distinguish between commission revenue and revenue from non-commission sources, which can be found in our form 10-K filed with the SEC on March 1, 2023.

FY 2023 Operational Priorities

1

Build on our progress within eHealth's omnichannel marketing and lead generation engine



2

Improve conversion rates across our entire enrollment platform



3

Introduce the next evolution of our customer retention strategy



4

Further diversify eHealth's revenue streams



FY 2023 Guidance

We are revising our guidance ranges for total revenue, GAAP net loss, and adjusted EBITDA to reflect the impact of the \$18.7 million in positive tail revenue we recognized in the second quarter, net of incremental bonus accrual of \$7 million. We are reiterating our original operating cash flow guidance range:

2023 Full Year Guidance	Original Range (in millions)	Current Range (in millions)
Total Revenue	\$420 – \$440	\$439 – \$459
GAAP Net Loss	\$55 – \$35	\$46 – \$26
Adjusted EBITDA ⁽¹⁾	\$(15) – \$5	\$(3) – \$17
Operating Cash Flow	\$(30) – \$(15)	\$(30) – \$(15)

(1) Adjusted EBITDA is calculated by excluding the impact from preferred stock, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, impairment, restructuring and other charges, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

Appendix

GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA Reconciliation

	(In thousands, unaudited)	
	Three Months Ended June 30,	
	2023	2022
GAAP net loss attributable to common stockholders	\$ (32,915)	\$ (45,029)
Preferred stock dividends	5,223	4,771
Change in preferred stock redemption value	4,191	2,756
GAAP net loss	(23,501)	(37,502)
Stock-based compensation expense	6,193	5,505
Depreciation and amortization	5,151	5,349
Impairment, restructuring and other charges	—	1,369
Other income (expense), net	(108)	1,167
Benefit from income taxes	(2,543)	(9,138)
Adjusted EBITDA	<u>\$ (14,808)</u>	<u>\$ (33,250)</u>

Reconciliation of Non-GAAP Financial Measures to Guidance

	(in millions, unaudited)	
	Full Year 2023 Guidance	
	Low	High
GAAP net loss attributable to common stockholders	\$ (84.0)	\$ (64.0)
Impact from preferred stock	38.0	38.0
GAAP net loss	(46.0)	(26.0)
Stock-based compensation expense	22.0	20.0
Depreciation and amortization	22.0	21.0
Impairment, restructuring and other charges	5.0	3.0
Other expense, net	7.0	6.0
Benefit from income taxes	(13.0)	(7.0)
Adjusted EBITDA	<u>\$ (3.0)</u>	<u>\$ 17.0</u>

